Monday, November 9, 2026

Neurocrine Biosciences Q3 Earnings Call Highlights

Nov 3, 2026. NBIB-’223, a Friedreich’s ataxia gene therapy being developed with Voyager Therapeutics, is expected to enter phase I in the coming months, with initial patient-level data anticipated in 2027.